Skip to main content Skip to main navigation menu Skip to site footer

Diagnosis of high-grade prostate cancer in patients with unexpectedly low prostate specific antigen levels: a rare case series

  • Ahmad Fauzan ,
  • Wahjoe Djatisoesanto ,


Abstract

Link of Video Abstract: https://youtu.be/PfhZ7H4kszQ

 

Background:  Prostate cancer is regarded as one of the most common leading causes of male cancer-related death worldwide. Clinicians agree that prostate specific antigen (PSA) is the best prostate cancer predictor. High PSA levels increase prostate cancer risk in most men. However, other research suggests that prostate cancer with low PSA levels is aggressive. In this uncommon case series, we present three high-grade prostate cancer patients with low PSA.

Case Description:  Between 2018 and 2019, three patients were referred for further therapeutic management after initial evaluation and treatment from secondary hospitals. All patients underwent complete diagnostic procedures including Laboratory examination, Pathological examination, and Radiologic imaging. PSA levels were 0.67 ng/mL, 4.0 ng/ml, and 4.93 ng/mL in the first, second, and third patients, respectively. The first two of three patients had a Gleason score (GS) of 9 (5+4), and one patient presented with GS of 8 (5+3). Distant metastatic disease was not found in our series. All of the patients underwent hormonal therapy, and none of them underwent radical prostatectomy. Follow-ups were completed in all patients, with the survival of 3 months, 4 months, and 12 months respectively.

Conclusion: High-grade prostate cancer in patients with low PSA levels emphasizes the need for rigorous history taking and physical examination and quick investigation of new biomarkers and criteria for prostate cancer detection. These patients' prognosis and optimal therapy are unknown. These patients have a worse prognosis than those with high PSA values, according to multiple studies.

Keywords: case series prostate cancer antigen diagnosis

References

  1. Sighinolfi MC, Rocco B. Re: EAU Guidelines: Prostate Cancer 2019. Eur Urol. 2019;76(6):871. Available from: http://dx.doi.org/10.1016/j.eururo.2019.07.014
  2. Indonesian Ministry of Health. National Guide on Managing Prostate Cancer. Publishing Department; Indonesian Ministry of Health; 1–32.
  3. Carter HB. Prostate cancers in men with low PSA levels--must we find them? N Engl J Med. 2004;350(22):2292–4. Available from: https://pubmed.ncbi.nlm.nih.gov/15163780
  4. Smith DS, Catalona WJ. Rate of Change in Serum Prostate Specific Antigen Levels as a Method For Prostate Cancer Detection. J Urol. 1994;152(4):1163–7. Available from: http://dx.doi.org/10.1016/s0022-5347(17)32528-4
  5. Agha RA, Sohrabi C, Mathew G, Franchi T, Kerwan A, O’Neill N, et al. The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. Int J Surg. 2020;84:231–5. Available from: http://dx.doi.org/10.1016/j.ijsu.2020.11.005
  6. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, et al. Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol. 2010/05/19. 2010;51(5):358–61. Available from: https://pubmed.ncbi.nlm.nih.gov/20495701
  7. Leibovici D, Spiess PE, Agarwal PK, Tu S-M, Pettaway CA, Hitzhusen K, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer. 2007;109(2):198–204. Available from: http://dx.doi.org/10.1002/cncr.22372
  8. Sella A, Konichezky M, Flex D, Sulkes A, Baniel J. Low PSA Metastatic Androgen– Independent Prostate Cancer. Eur Urol. 2000;38(3):250–4. Available from: http://dx.doi.org/10.1159/000020289
  9. Hussain A, Aly A, Daniel Mullins C, Qian Y, Arellano J, Onukwugha E. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis. Cancer Med. 2016/10/11. 2016;5(11):3300–9. Available from: https://pubmed.ncbi.nlm.nih.gov/27730756
  10. Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2014;65(1):3–6. Available from: http://dx.doi.org/10.1016/j.eururo.2013.09.024
  11. Halabi S, Kelly WK, Zhou H, Armstrong AJ, Quinn D, Fizazi K, et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials. J Clin Oncol. 2014;32(15_suppl):5002. Available from: http://dx.doi.org/10.1200/jco.2014.32.15_suppl.5002
  12. Guo Y, Mao S, Zhang A, Zhang J, Wang L, Wang R, et al. Survival Significance of Patients With Low Prostate-Specific Antigen and High-Grade Prostate Cancer After Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy. Front Oncol. 2019;9:638. Available from: https://pubmed.ncbi.nlm.nih.gov/31380277
  13. Kim YW, Park YK, Park JH, Lee J, Lee SJ, Kim J Il, et al. Adenosquamous carcinoma of the prostate. Yonsei Med J. 1999;40(4):396. Available from: http://dx.doi.org/10.3349/ymj.1999.40.4.396
  14. Cecen K, Karadag MA, Demir A, Kocaaslan R. Small cell carcinoma of the prostate presenting with skin metastasis: a case report. J Med Case Rep. 2014;8:146. Available from: https://pubmed.ncbi.nlm.nih.gov/24885487
  15. Landy R, Houghton LC, Berg CD, Grubb RL 3rd, Katki HA, Black A. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020;13(4):367-376. Available from: doi: 10.1158/1940-6207.CAPR-19-0397.
  16. Nishio R, Furuya Y, Nagakawa O, Fuse H. Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol. 2003;35(2):189–92. Available from: http://dx.doi.org/10.1023/b:urol.0000020306.08275.49
  17. Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592-599. Available from: doi: 10.1002/cncr.30474.
  18. Tu S-M, Lin S-H, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002;3(8):508–13. Available from: http://dx.doi.org/10.1016/s1470-2045(02)00820-3
  19. Miranti IP, Istiadi H, Larasati PAA, Wijaya I, Puspasari D, Karlowee V. Prostate acinar adenocarcinoma: a comparative study of Her-2 and Ki-67 expression on Gleason patterns. Bali Med J. [Internet]. 2021;10(2):677-82. Available from: https://balimedicaljournal.org/index.php/bmj/article/view/2251
  20. Rosita L, Occifa GA. Analysis of Prostate Specific Antigen (PSA) level on Medical Check-up (MCU) Participants. Bali Med J. 2019;8(1):267-9. Available from: https://balimedicaljournal.org/index.php/bmj/article/view/1345

How to Cite

Fauzan, A., & Djatisoesanto, W. . (2023). Diagnosis of high-grade prostate cancer in patients with unexpectedly low prostate specific antigen levels: a rare case series. Bali Medical Journal, 12(2), 1718–1723. https://doi.org/10.15562/bmj.v12i2.4486
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
14

Total
11

Share

Search Panel

Ahmad Fauzan
Google Scholar
Pubmed
BMJ Journal

Wahjoe Djatisoesanto
Google Scholar
Pubmed
BMJ Journal